J Biol Chem, Vol. 274, Issue 40, 28521-28527, October 1, 1999
The Brn-3a Transcription Factor Plays a Critical Role in
Regulating Human Papilloma Virus Gene Expression and Determining the
Growth Characteristics of Cervical Cancer Cells*
Daniel
Ndisang,
Vishwanie
Budhram-Mahadeo, and
David S.
Latchman
From the Department of Molecular Pathology, Windeyer Institute of
Medical Sciences, University College London, London W1P 6DB,
United Kingdom
 |
ABSTRACT |
The Brn-3a POU family transcription factor has
previously been shown to activate the human papilloma virus type 16 (HPV-16) promoter driving the expression of the E6- and E7-transforming proteins. Moreover, Brn-3a is overexpressed approximately 300-fold in
cervical biopsies from women with cervical intra-epithelial neoplasia
type 3 (CIN3) compared with normal cervical material. To test the role
of Brn-3a in cervical neoplasia we have manipulated its expression in
cervical carcinoma-derived cell lines with or without endogenous HPV
genes. In HPV-expressing cells, reduction in Brn-3a expression
specifically reduces HPV gene expression, growth rate, saturation
density and anchorage-independent growth, whereas these effects are not
observed when Brn-3a expression is reduced in cervical cells lacking
HPV genomes. Together with our previous observations, these findings
indicate a critical role for Brn-3a in regulating HPV gene expression
and thereby in controlling the growth/transformation of cervical cells.
 |
INTRODUCTION |
It is now generally accepted that the oncogenic human papilloma
viruses types 16 and 18 (HPV-16 and
HPV-18)1 play a key role in
cervical cancer. Thus these viruses encode specific transforming
proteins (E6, E7) and are found in the great majority of women with
cervical cancer (1-3). Despite this, however, both HPV-16 and HPV-18
can be detected in women with undetectable or minimal cervical
abnormality (4, 5). It is therefore unclear what factors trigger HPV-16
or HPV-18 to initiate the transformation of cervical cells to a
malignant phenotype. It has recently been shown that one potential
mechanism for regulating HPV-induced transformation is the regulation
of the activity of the transforming proteins E6 and E7. Thus, a natural
polymorphism exists in the human population with some individuals
having a p53 tumor suppressor protein with a proline residue at
position 72, whereas others have an arginine at this position (6). As p53 with an arginine residue is more efficiently degraded by the HPV E6
protein, individuals with this amino acid have a higher risk of
cervical cancer caused by HPV (6).
Evidently, another potential mechanism for regulating transformation by
HPV would be the control of the production of the E6 and E7 proteins by
cellular regulatory factors. Thus, it has been shown that the upstream
regulatory region (URR) of the virus genome, which controls the
expression of the genes encoding E6 and E7, is specifically active in
cervical cells (7, 8), and it has therefore been suggested that the
regulation of HPV URR activity by cellular transcription factors may
play a key role in regulating viral transforming activity in different
cell types and different individuals (9). However, although numerous studies have documented binding of several cellular transcription factors to the URR (10-13), these factors are generally ubiquitously expressed and may not therefore fully explain the cervical
cell-specific activity of the URR or its activation leading to
transformation in vivo.
In previous studies, we showed that a sequence ATGCAATT in the region
of the URR that confers cervical specific activity was able to
stimulate URR activity in cervical cell lines while inhibiting its
activity in noncervical cells (14). Thus, this motif binds the
ubiquitously expressed POU family transcription factor Oct-1, which
represses its activity in noncervical cells (14, 15). Conversely, in
cervical cells this motif can, in addition, bind the POU family
transcription factors Brn-3a and Brn-3b, which were originally
identified in neuronal cells (16-18) but that are also expressed in
cervical cells but not by other cell types (17). Brn-3a (also known as
Brn-3.0 (16, 17)) and Brn-3b (also known as Brn-3.2 (17, 18)) are
members of the POU family of transcription factors (for reviews see
Refs. 19 and 20), which are closely related to one another but are
encoded by distinct genes (21). Most interestingly, Brn-3a activates
transcription directed by the HPV URR, and this effect is dependent on
the ATGCAATT motif (22). Conversely, Brn-3b represses such
transcription via the ATGCAATT motif and interferes with activation by
Brn-3a (22).
In view of the possibility that the balance between Brn-3a and
Brn-3b expression might play a key role in determining the activity of
the HPV URR and therefore the progression of cervical cancer, we
previously examined the expression of these factors in cervical
biopsies from women with no detectable cervical abnormality and those
with cervical intra-epithelial neoplasia grade 3 (CIN3) lesions. Most
interestingly, although the level of Brn-3b expression was similar in
the two groups, the mean level of Brn-3a was elevated more than
300-fold in the samples from women with CIN3 compared with the normal
samples (23).
Evidently this finding taken together with the ability of Brn-3a to
activate the HPV URR raises the possibility that elevated levels of
Brn-3a may be critical for E6 and E7 gene expression in cervical
cancer. We have therefore investigated the effect of artificially
manipulating the levels of Brn-3a on HPV gene expression in cervical
cancer cell lines and on their growth and transformation characteristics.
 |
MATERIALS AND METHODS |
Plasmid Constructs--
The expression vector pLTRpoly(ATCC)
containing the full-length cDNAs of the class IV POU domain
transcription factors Brn-3a and Brn-3b under the Moloney
murine leukemia virus promoter have previously been
described (27). The antisense Brn-3a construct was cloned
within the pJ5 vector polylinker under the control of the
glucocorticoid-inducible mouse mammary tumor virus promoter (28).
Stable Transfection and Isolation of Clonal Cell Lines--
SiHa
(ATCC) and C33 (ATCC) cell lines were grown in minimum essential medium
(Eagle's) with Earle's buffered saline solution supplemented with
10% fetal bovine serum, 0.1 mM nonessential amino acids,
and 1.0 mM sodium pyruvate. The Brn-3 expression vectors
were cotransfected with pci-neo (Promega) neomycin-resistant vector
into both cell lines by calcium phosphate-mediated transfection method
(30). Typically, 15 µg of the respective recombinants plus 3 µg of
the neomycin-resistant plasmid were co-transfected into 80%
subconfluent SiHa and C33 cells in 10-cm plates, and media were
supplemented subsequently with G418 (Life Technologies, Inc.) to a
final concentration of 800 µg/ml. Putative clones began emerging
after about 10 days and were subsequently isolated with cloning rings
and cultured in medium supplemented with 800 µg/ml G418. Antisense
and control clones were treated with 1 µM dexamethasone 24 h before protein extraction.
Western Blotting--
Harvested cells were resuspended in 100 µl of extraction buffer (20 mM Hepes (pH 7.8), 450 mM NaCl, 0.4 mM EDTA, 0.5 mM
dithiothreitol, 25% glycerol 0.05 mM phenylmethylsulphonyl
fluoride) and freeze-thawed. The protein concentration of the
supernatant was determined, and the samples used for SDS-polyacrylamide
gel electrophoresis as earlier reported (23) although with some
modification for HPV-E6 protein analysis with shorter
SDS-polyacrylamide gel electrophoresis resolution time. The gel was
blotted onto membrane (Amersham Pharmacia Biotech), and the membrane
was blocked for 2 h with 10% Marvel (fat-free milk) and incubated
with 1:500 HPV-16-E6 antibody (Santa Cruz) for 16 h overnight at
4 °C, washed 5 times with 0.1% Tween 20, then incubated with
horseradish peroxidase-conjugated mouse secondary antibody (Santa Cruz)
for 1 h.
Analysis of Cellular Growth Rate and Saturation Density--
To
analyze the growth rate of both the parental and clonal cells, a basic
method of counting the amount of viable cells in a hemacytometer
chamber using a light microscope was employed. Routinely, each putative
clone or control cell was seeded with an initial density of 1 × 104 cells in three groups of eight. At regular intervals of
8, 16, and 24 h, subsequent groups of three were trypsinized,
washed, resuspended in appropriate percentage of trypan blue medium,
and then counted. For determination of the saturation density, the same
method was used except for the longer time interval of about 3 days,
during which the cells were allowed to proliferate freely without passage.
Anchorage-independent Growth--
Determination of
anchorage-independent proliferation was established by growing cells in
soft agar. 3 ml of 103 clonal or parental cells resuspended
in low melting point agarose (Life Technologies, Inc.) dissolved in
G418 supplemented media with or without dexamethasone to a final
constitution of 0.33% was overlaid in triplicate 60-mm plates
containing 0.5% low melting point agarose dissolved in appropriate
medium. The plates were immediately incubated at 37 °C, and colonies
were scored after 10 days.
 |
RESULTS |
To investigate the effect of manipulating the expression of Brn-3a
in cervical cancer cell lines, we utilized the SiHa cell line, which
contains a single integrated HPV-16 genome and, for comparison, the
C33-transformed cervical cell line, which does not contain any HPV DNA
(24-26). To overexpress Brn-3a, the cells were transfected with an
expression vector in which expression of Brn-3a is driven by the
moloney murine leukemia virus promoter, which we have previously used
to successfully overexpress Brn-3a in neuronal cells (27). A similar
vector was also used to overexpress Brn-3b in these cells for
comparison. Similarly, to reduce the level of endogenous Brn-3a, we
used a construct in which an antisense transcript of Brn-3a is produced
under the control of the glucocorticoid-inducible mouse mammary tumor
virus promoter, which we have similarly previously used to reduce
Brn-3a levels in neuronal cells (28). Similar transfections were also
carried out using the expression vectors lacking any insert to
produce control cell lines. In each case, stably transfected cell lines
were selected on the basis of their neomycin resistance, which was
encoded on the plasmid vector. In each case, several cell lines were
isolated from different culture plates to control for clonal variation.
Clonal cell lines isolated in this way were first tested to determine
whether they contained altered levels of Brn-3a as determined by
Western blotting with a specific antibody. In these experiments (Fig.
1) clear overexpression of Brn-3a was
observed in several cell lines transfected with the Brn-3a expression
vector compared either to parental untransfected cells, cells
transfected with the expression vector alone, or cells transfected with
the Brn-3b expression vector. In contrast, several cell lines obtained
by transfection with the Brn-3a antisense construct showed only minimal reduction of Brn-3a levels in the absence of dexamethasone to induce
the mouse mammary tumor virus promoter. However, a clear reduction in
Brn-3a levels was observed in several of these cell lines when the
cells were treated with dexamethasone, resulting in the induction of
the antisense construct. This effect was observed in both the SiHa
cells and in the C-33 cells transfected with the Brn-3a antisense
construct (Fig. 1). In contrast, no effect of dexamethasone on
endogenous Brn-3a levels was observed in either of the parental cell
lines when treated with dexamethasone or in the cell lines transfected
with expression vector lacking any insert (data not shown). Similarly,
no alteration in exogenous Brn-3a levels in response to dexamethasone
was observed in the cell lines obtained by transfection with the Brn-3a
sense construct under the control of the Moloney murine leukemia virus
promoter.

View larger version (15K):
[in this window]
[in a new window]
|
Fig. 1.
Panel a, Western blot showing Brn-3a and
actin levels in SiHa cells either transfected with expression vector
lacking any insert (track 1) or transfected with Brn-3a
antisense vector and grown in the presence of dexamethasone (tracks
2 and 3) or in the absence of dexamethasone
(tracks 4 and 5). Panels b and
c, quantitative determination of the levels of Brn-3a
protein based on densitometric scanning of data of the type shown in
panel a in parental SiHa (cross, panel
b) or C-33 cells (cross, panel c) cells or
clonal cell lines transfected with expression vector lacking any insert
(pci-neo, ), Brn-3a expression vector ( ), Brn-3b expression
vector ( ), or a vector expressing the antisense strand of the Brn-3a
gene ( ) and then grown in the presence ( ) or absence ( ) of
dexamethasone. Each data point shows a different independently isolated
clonal cell line.
|
|
These data thus indicate that the cell lines engineered to overexpress
Brn-3a do indeed show a specific elevation of Brn-3a levels, whereas
the antisense cell lines show decreased expression of Brn-3a,
particularly when grown in the presence of dexamethasone to induce the
antisense construct. The cell lines showing the greatest elevations or
reductions in Brn-3a levels were selected for further study. Similarly,
the SiHa and C33 cell lines over-engineered to express Brn-3b showed a
specific elevation of Brn-3b levels, which was not observed in the
other cell lines (data not shown).
To determine whether these alterations in Brn-3a and Brn-3b levels did
produce a change in the level of HPV gene expression driven by the URR
promoter, the cellular extracts were also Western-blotted with antibody
to the HPV E6 protein. In these experiments (Fig. 2) the SiHa cells engineered to
overexpress Brn-3a showed no significant increase in HPV expression
over the control parental SiHa cells or SiHa cells containing only
plasmid vector, suggesting that HPV gene expression is likely to be
maximally stimulated by the endogenous Brn-3a present in the SiHa
cells. Interestingly, however, the cells engineered to overexpress
Brn-3b showed a small decrease in HPV gene expression. A small decrease
in HPV gene expression was also observed in both the cell lines
containing the antisense construct. Most importantly, a significant
further decrease in HPV gene expression was observed in both these cell
lines upon treatment with dexamethasone to fully induce the antisense
constructs. In contrast, no effect of dexamethasone on HPV expression
was observed in the parental SiHa cells (Fig. 2), confirming that this
effect was dependent upon the activation of the antisense construct by
dexamethasone rather than on a direct inhibitory effect of
dexamethasone on HPV gene expression. Interestingly, the decrease in
HPV gene expression was greatest in antisense cell line 5, paralleling
the greater reduction in Brn-3a levels in this cell line compared with
the antisense cell line 3. As expected, no HPV gene expression was
detected in any of the cell lines derived from C-33 cells, which are
not transformed with HPV.

View larger version (47K):
[in this window]
[in a new window]
|
Fig. 2.
Levels of HPV E6 protein in the various cell
lines. Panel a shows a typical Western blot with the
antibodies to E6 (A) or actin control (B) using
extracts from SiHa neo cells grown in the presence (track 1)
or absence (track 2) of dexamethasone, the Brn-3a antisense
clone 3 grown in the presence (track 3) or the absence
(track 4) of dexamethasone, and cells overexpressing Brn-3a
(track 5) or Brn-3b (track 6) in the absence of
dexamethasone. Panel b shows quantitative data for parental
SiHa cells (Siha) or clonal cell lines transfected with
Brn-3a expression vector (SihaA), Brn-3b
expression vector (SihaB), or two different cell
lines transfected with the Brn-3a antisense vector ( 3A clone 3 ( 3A3) and 3A clone 5 ( 3A5)). Data for the parental
cells or the antisense cells are shown for cells grown in the absence
or presence (dex) of dexamethasone.
|
|
These data indicate therefore that the HPV gene expression that occurs
in the SiHa cell line appears to be dependent upon the expression of
Brn-3a in these cells since it can be specifically reduced by
decreasing Brn-3a levels using an antisense approach. We therefore
wished to establish whether such alteration in HPV gene expression
mediated via Brn-3a resulted in alterations in the growth rate of the
manipulated cells. Evidently, the C33 cells serve as an important
control for these experiments, since any direct effect of manipulating
Brn-3a levels on cellular growth would also be observed in these cells,
whereas this would not be the case if the effect in SiHa cells is
mediated via the alteration in HPV gene expression that would not occur
in the C33 cells. We therefore measured the growth rate of the various
different clones over a 72-h period. In the experiments with the SiHa
clones, the parental SiHa cells and the cells transfected with empty
expression vector alone showed a similar growth rate (Fig.
3a), indicating that the
selection of stably transfected cell lines does not produce cell lines
with enhanced growth rates. Interestingly, overexpression of Brn-3a
resulted in a marginally enhanced growth rate of the SiHa cells,
whereas overexpression of Brn-3b produced a significantly reduced
growth rate (Fig. 3a). Most importantly, although the cells
engineered with antisense Brn-3a showed a similar growth rate to
parental cells in the absence of dexamethasone, their growth rate
was dramatically reduced by treatment by dexamethasone, although this
treatment had no effect on the growth of parental cells (Fig.
3b).

View larger version (15K):
[in this window]
[in a new window]
|
Fig. 3.
Cell growth curves of SiHa cells. The
growth rate of parental SiHa cells is compared with that of SiHa cells
transfected with empty expression vector (neo), Brn-3a expression
vector (A), Brn-3b expression vector (B), or the antisense Brn-3a
( 3 A) vector in the presence or absence of
dexamethasone. Similar results were obtained in three independent
experiments. Panel a: , SiHa; , SiHaA; , SiHa-neo;
*, SiHaB. Panel b: , ShHa; , ShHa + dexamethasone;
, Si( 3A); *, Si( 3A) + dexamethasone.
|
|
These experiments thus indicate that the reduced Brn-3a expression in
the antisense SiHa cells is paralleled not only by reduced HPV
gene expression but also by reduced growth rate. In similar experiments
in the HPV-negative C-33 cells (Fig. 4),
all the cell lines showed similar growth rates. Hence, manipulating the
expression of Brn-3a or Brn-3b in a cervical cell line that does not
express HPV does not result in altered growth rates.

View larger version (13K):
[in this window]
[in a new window]
|
Fig. 4.
Cell growth curves of C-33 cells. The
growth rate of parental C-33 cells is compared with that of C-33 cells
transfected with empty expression vector (neo), Brn-3a expression
vector (A), Brn-3b expression vector (B), or the antisense Brn-3a
vector ( 3 A) in the presence or absence of
dexamethasone. Similar results were obtained in three independent
experiments. Panel a, , C33; , C33 + dexamethasone;
, C33A; *, C33B. Panel b: , C33; , C33 + dexamethasone; , C33( 3A) *; C33( 3A) + dexamethasone.
|
|
As well as measuring the effect of manipulating Brn-3a expression on
cellular growth rate, we also wished to determine whether such
manipulation would affect the saturation density of the cells, since
the loss of contact inhibition resulting in growth to higher densities
is characteristic of cancer cells. The various cell lines were
therefore plated out and grown over a period of several days to
determine their saturation density. In these experiments (Fig.
5), similar saturation densities were
observed in the parental SiHa cells, the cells transfected with plasmid
expression vector alone, and the cells overexpressing Brn-3a. However,
a clearly reduced saturation density was observed in the SiHa cells
overexpressing Brn-3b (Fig. 5a). Similarly, two distinct
SiHa cell lines containing the transfected antisense construct showed a
clear reduction in saturation density compared with the parental cells
(Fig. 5b). This reduction was greater in cell line 5 compared with cell line 3, paralleling the greater reduction in HPV
gene expression in this cell line (see Fig. 2). Moreover, the
saturation density of both the antisense cell lines was further reduced
by full induction of antisense expression using dexamethasone, whereas
no effect on saturation density was observed when the parental
cells were treated in this way, confirming that this effect was
specific to the cells containing the antisense construct (Fig.
5b). As in the cell growth experiments, all the C-33-derived
cell clones showed similar saturation densities that were unaffected by
dexamethasone (Fig. 6), indicating that
the effects in SiHa cells correlate with the effect of Brn-3a on HPV
gene expression.

View larger version (13K):
[in this window]
[in a new window]
|
Fig. 5.
Saturation density of parental SiHa cells or
SiHa-derived clones stably transfected with empty expression vector
(neo), Brn-3a expression vector (A), Brn-3b expression vector (B), or
two cell lines ( 3A clone 3 ( 3 A3) and
3A clone 5 ( 3 A5)) transfected with the
antisense Brn-3a vector. Data for parental cells or the antisense
cells is shown for cells grown in the presence or absence of
dexamethasone. Similar results were obtained in three independent
experiments. Panel a: , SiHa; , SiHa-neo; , SiHaA;
*, SiHaB. Panel b: , SiHa; , SiHa + dexamethasone;
, Si( 3A3); *, Si( 3A3) + dexamethasone; , Si( 3A5); ,
Si( 3A5) + dexamethasone.
|
|

View larger version (10K):
[in this window]
[in a new window]
|
Fig. 6.
Saturation density of parental C-33 cells or
C-33-derived clones stably transfected with empty expression vector
(neo), Brn-3a expression vector (A), Brn-3b expression vector (B), or
the antisense Brn-3a vector ( 3 A), and
grown in the presence or absence of dexamethasone. Similar results
were obtained in three independent experiments. Panel a:
, C33; , C33-neo; , C33A; *, C33B. Panel b: ,
C33; , C33 + dexamethasone; , C33( 3A); *, C33( 3A) + dexamethasone.
|
|
Having established the effect of manipulating Brn-3a expression on the
growth and saturation density of the cell lines when grown attached to
culture dishes, we wished to determine the effect of such manipulation
on their ability to grow in an anchorage-independent manner, since this
is an important feature of tumor cells necessary for their growth
in vivo. We therefore measured the ability of the various
cell lines to form colonies in soft agar. As indicated in Fig.
7a, the SiHa cells showed a
clear ability to form colonies in soft agar as expected, and this was
not affected in the cells containing the plasmid expresion vector or in
the cells overexpressing Brn-3a.

View larger version (19K):
[in this window]
[in a new window]
|
Fig. 7.
Anchorage-independent growth as
assayed by colony-forming efficiency (cfe) (number of
colonies formed/number of colonies seeded ×100). The result is show for parental SiHa
cells and SiHa-derived clonal cell lines transfected with empty
expression vector (neo), Brn-3a expression vector
(A), Brn-3b expression vector (B), or the Brn-3a
antisense vector ( 3A) (panel a) or for parental
C-33 cells and similarly transfected stable cell lines derived from
C-33 (panel b). Values are the mean of three separate
determinations. Data shown for two different SiHa antisense cell lines
(-3A clone 3 ( 3A3)) and 3A clone 5 ( 3A5)). For parental SiHa cells and the antisense
cells, data is shown for the assay carried out in the presence or
absence of dexamethasone (dex).
|
|
However, a significantly reduced rate of colony formation in soft agar
was observed in the cells overexpressing Brn-3b, paralleling their
reduced growth rate and saturation density when grown attached to
culture dishes (p < 0.05 for SiHa-neo compared with
SiHa B). Moreover, a still greater reduction in colony formation of
approximately 4-fold was observed in the two different cell lines
containing the antisense Brn-3a construct (Fig. 7a). This
colony formation was reduced even further upon treatment of the
antisense cells with dexamethasone, with colony formation being
virtually undetectable in cell line 5, paralleling its greater
reduction in HPV gene expression and saturation density
(p < 0.05 for each antisense line compared with
parental cells). This effect of dexamethasone was specific to the
antisense cell lines, since no effect of dexamethasone on colony
formation was observed in the parental cells.
To determine whether these effects of manipulating Brn-3a levels on
anchorage-independent growth were dependent upon the altered level of
HPV gene expression, we carried out similar experiments in the
C-33-derived cell lines. As illustrated in Fig. 7b, however, all the various cell lines showed a similar ability to form colonies in
soft agar, which was not in any way affected by the alteration of
Brn-3a or Brn-3b levels, with no significant differences being noted
between the various cell lines (p > 0.05 in all
cases). Hence, the effects on anchorage-independent growth observed in the SiHa cell lines are correlated with the effect of Brn-3a on HPV
gene expression in the same manner as the effect on the growth of cells
attached to culture dishes.
 |
DISCUSSION |
In this report we have demonstrated for the first time that the
manipulation of Brn-3a expression can affect the levels of gene
expression from an integrated HPV genome in a transformed cervical cell
line. Thus, SiHa cell lines transfected with an antisense Brn-3a
expression plasmid showed a clearly reduced expression of HPV. Hence,
the expression of the single endogenous HPV genome in SiHa cells
appears to depend upon the expression of Brn-3a in these cells such
that when Brn-3a expression is reduced, HPV gene expression is
correspondingly reduced. This effect evidently parallels our
previous finding that the ATGCAATT motif in the HPV URR can be
transactivated by Brn-3a in co-transfection assays involving
promoter-reporter constructs (22) and extends such transactivation to
an endogenous HPV genome. Interestingly, despite the increased Brn-3a
levels observed in cells transfected with an expression vector for
Brn-3a, the levels of HPV gene expression were not significantly
increased, suggesting that HPV gene expression is already maximally
stimulated in SiHa cells by the significant level of endogenous Brn-3a
in these cells. Interestingly however, HPV gene expression could be
reduced by overexpressing Brn-3b in SiHa cells, paralleling the ability
of Brn-3b to repress URR activity via the ATGCAATT motif in
co-transfection experiments (22).
These experiments thus establish Brn-3a expression as being critical
for the maintenance of HPV gene transcription in a cervical cancer cell
line. In this report we have also demonstrated that the growth
characteristics of such a cell line are similarly dependent upon
Brn-3a. Thus, the inhibition of Brn-3a expression using an antisense
approach led to reduced cellular growth rate, saturation density, and
the ability to grow in an anchorage-independent manner. Several lines
of evidence indicate that this effect is dependent upon the ability of
Brn-3a to modulate HPV gene expression rather than to a direct effect
of Brn-3a on the cell. Thus, no effect of reduced Brn-3a levels on
cellular growth, saturation density, or anchorage independence was
observed in the C-33 cells, which showed a similar reduction in Brn-3a
levels but that are not transformed with HPV. Similarly, overexpression
of Brn-3b in the SiHa cells, which also reduced HPV gene expression,
also resulted in reduced growth rate, saturation density, and
anchorage-independent growth, although the effects were not as dramatic
as reducing Brn-3a levels, paralleling the less dramatic effect of
overexpressing Brn-3b on HPV gene expression. Last, it should be noted
that in the C4-1 cervical carcinoma cell line, reduction of E6 and E7
expression with an antisense approach similarly resulted in reduced
cellular proliferation (29).
Thus, simply by manipulating Brn-3a levels it is possible to alter HPV
oncogene expression and thereby alter the growth characteristics of the
tumor cells in terms not only of growth rate and independence from
contact inhibition but, most importantly, in terms of anchorage independence, which is a key requirement for tumorigenesis in vivo. This association of Brn-3a with HPV gene expression and the
characteristics of transformed cervical cells is of particular interest
in view of our previous finding that Brn-3a is overexpressed in the
transformation zone of women with CIN3 compared with women with no
detectable cervical abnormality (23). Such overexpression of
Brn-3a is likely therefore, in view of our current results, to
play a key role in the elevated HPV gene expression observed in the
transformed cells, which is critical for oncogenic transformation.
Hence the elevated levels of Brn-3a observed in CIN3 material and
in cervical cancer cell lines appear to play a key role in the elevated
expression of HPV and thereby in determining the transformed phenotype.
These considerations evidently focus attention on the manner in which
Brn-3a expression becomes elevated in women with CIN3. In our previous
study (23) we were able to show that similar elevated expression of
Brn-3a occurs in histologically normal segments of the cervix adjacent
to the CIN3 region that do not contain detectable HPV DNA or RNA, and
we have now extended these findings to show that Brn-3a expression is
elevated throughout the cervix in women with
CIN3.2 This widespread
elevation in Brn-3a levels in women with CIN3 may be dependent upon
their exposure to an environmental factor that raises Brn-3a levels, or
alternatively, could reflect a genetic difference in the Brn-3a gene
regulatory region, which results in elevated expression of Brn-3a in
these women. In this latter case, this genetic polymorphism would
represent a risk factor for cervical cancer similar to having a
p53 gene encoding a protein with an arginine at position 72, resulting in enhanced degradation by the HPV E6 protein (6).
Whatever the cause of the elevated level of Brn-3a, however, it is
clear that in individuals having such elevation, infection with HPV-16
or HPV-18 will result in the activation of the HPV URR, leading to E6
and E7 expression and cellular alterations in the cervical
transformation zone at the junction of the endocervix and the
ectocervix, where cervical tumors appear. Hence the elevated levels of
Brn-3a, whether caused by environmental or genetic causes, would play a
critical role in activation of viral transcription and disease
progression, although other factors such as viral type, viral
distribution, and cellular susceptibility to transformation would be
responsible for the precise localization of the malignant lesions.
Most importantly, the fact that the level of HPV gene expression and
the abnormal growth characteristics of cervical cancer cells can be
reversed by reduction of Brn-3a expression makes this factor an
attractive target for therapeutic intervention. This could involve the
reduction of endogenous Brn-3a expression either by pharmacological
manipulations to reduce the activity of the Brn-3a gene promoter or by
the use of gene delivery vectors to deliver Brn-3a antisense constructs
similar to those utilized here. To investigate further the potential
utility of such forms of therapy, it will be necessary to investigate
whether the SiHa cells with reduced Brn-3a levels show reduced
tumorigenicity when grown in nude mice and also whether the growth rate
of an established tumor can be manipulated in vivo by using
viral vectors expressing the antisense strand of the Brn-3a
gene. It is already clear, however, from the experiments described here
that the Brn-3a factor, which is overexpressed in women with CIN3,
plays a key role in HPV gene transcription and thereby regulates the
growth characteristics of cervical carcinoma cells.
 |
ACKNOWLEDGEMENT |
This work was supported by Wellbeing
(the health research charity for women and babies).
 |
FOOTNOTES |
*
The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
To whom correspondence should be addressed: Dept. of Molecular
Pathology, Windeyer Institute of Medical Sciences, University College
London, The Windeyer Building, Cleveland St., London W1P 6DB, UK. Tel.:
44-171-504-9343; Fax: 44-171-387-3310; E-mail: d.latchman@ucl.ac.uk.
2
D. Ndisang, unpublished data.
 |
ABBREVIATIONS |
The abbreviations used are:
HPV, human papilloma
virus;
URR, upstream regulatory region;
CIN, cervical intra-epithelial
neoplasia.
 |
REFERENCES |
| 1.
|
Schiffman, M. H.,
Bauer, H. M.,
Hoover, R. N.,
Glass, A. G.,
Cadell, D. M.,
Rush, B. B.,
Scott, D. R.,
Sherman, M. E.,
Kurman, R. J.,
and Wacholder, S.
(1983)
J. Natl. Cancer Inst.
85,
958-964[Abstract/Free Full Text]
|
| 2.
|
Durst, M.,
Gissmann, L.,
Ikenberg, H.,
and Zur Hausen, H.
(1983)
Proc. Natl. Acad. Sci. U. S. A.
80,
3812-3815[Abstract/Free Full Text]
|
| 3.
|
Burghardt, E.
(1984)
Clin. Obstet. Gynecol.
11,
239-257
|
| 4.
|
Cox, M. F.,
Meanwell, C. A.,
Maitland, N. J.,
Blackledge, G.,
Scully, C.,
and Jordan, J. A.
(1986)
Lancet
2,
157-158[CrossRef][Medline]
[Order article via Infotrieve]
|
| 5.
|
Meanwell, C. A.
(1987)
Lancet
1,
703-707[Medline]
[Order article via Infotrieve]
|
| 6.
|
Storey, A.,
Thomas, M.,
Kalita, A.,
Harwood, C.,
Gardiol, D.,
Mantovani, F.,
Breuer, J.,
Leigh, I. M.,
Matlashewsko, G.,
and Banks, L.
(1998)
Nature
393,
229-234[CrossRef][Medline]
[Order article via Infotrieve]
|
| 7.
|
Cripe, T. C.,
Hangen, T. H.,
Turk, J. P.,
Tabatabai, F.,
Schmid, P. G.,
Duerst, M.,
Gissmann, L.,
Roman, A.,
and Twek, L.
(1987)
EMBO J.
6,
3745-3753[Medline]
[Order article via Infotrieve]
|
| 8.
|
Gloss, B.,
Bernard, H. U.,
Seedorf, K.,
and Klock, G.
(1987)
EMBO J.
6,
3735-3743[Medline]
[Order article via Infotrieve]
|
| 9.
|
Zur Hausen, H.
(1986)
Lancet
2,
489-491[Medline]
[Order article via Infotrieve]
|
| 10.
|
Chan, W-K.,
Chong, T.,
Benard, H-U.,
and Klock, G.
(1990)
Nucleic Acids Res.
18,
763-769[Abstract/Free Full Text]
|
| 11.
|
Chan, W-K.,
Klock, G.,
and Bernard, H-U.
(1989)
J. Virol.
63,
3261-3269[Abstract/Free Full Text]
|
| 12.
|
Gloss, B.,
Yeo-Gloss, M.,
Meisterenst, M.,
Rogge, L.,
Wimacker, E. L.,
and Bernard, H-U.
(1989)
Nucleic Acids Res.
17,
3519-3533[Abstract/Free Full Text]
|
| 13.
|
Nakshatri, H.,
Pater, M. M.,
and Pater, A.
(1990)
Virology
178,
92-103[CrossRef][Medline]
[Order article via Infotrieve]
|
| 14.
|
Morris, P. J.,
Dent, C. L.,
Ring, C. J. A.,
and Latchman, D. S.
(1993)
Nucleic Acids Res.
21,
1019-1023[Abstract/Free Full Text]
|
| 15.
|
Dent, C. L.,
McIndoe, G. A.,
and Latchman, D. S.
(1991)
Nucleic Acids Res.
19,
4531-4535[Abstract/Free Full Text]
|
| 16.
|
Gerrero, M. R.,
McEvilly, R. J.,
Tuner, E.,
Lin, C. R.,
O'Connell, S.,
Jenne, K. J.,
Hobbs, M. V.,
and Rosengield, M. G.
(1993)
Proc. Natl. Acad. Sci. U. S. A.
90,
10841-10845[Abstract/Free Full Text]
|
| 17.
|
Lillycrop, K. A.,
Budhram-Mahadeo, V. S.,
Lakin, N. D.,
Terrenghi, G.,
Wood, J. N.,
Polak, J. M.,
and Latchman, D. S.
(1992)
Nucleic Acids Res.
20,
5093-5096[Abstract/Free Full Text]
|
| 18.
|
Turner, E. E.,
Jenne, K. J.,
and Rosenfeld, M. G.
(1994)
Neuron
12,
205-218[CrossRef][Medline]
[Order article via Infotrieve]
|
| 19.
|
Verrijzer, C. P.,
and van der Vliet, P. C.
(1993)
Biochim. Biophys. Acta
1173,
1-21[Medline]
[Order article via Infotrieve]
|
| 20.
|
Wegner, M.,
Drolet, D. W.,
and Rosenfeld, M. G.
(1993)
Curr. Opin. Dev. Biol.
5,
488-498
|
| 21.
|
Theil, T.,
McLean-Hunter, S.,
Zornig, M.,
and Möröy, T.
(1993)
Nucleic Acids Res.
21,
5921-5929[Abstract/Free Full Text]
|
| 22.
|
Morris, P. J.,
Theil, T.,
Ring, C. J. A.,
Lillycrop, K. A.,
Möröy, T.,
and Latchman, D. S.
(1994)
Mol. Cell. Biol.
14,
6907-6914[Abstract/Free Full Text]
|
| 23.
|
Ndisang, D.,
Morris, P. J.,
Chapman, C.,
Ho, L.,
Singer, A.,
and Latchman, D. S.
(1998)
J. Clin. Invest.
101,
1687-1692[Medline]
[Order article via Infotrieve]
|
| 24.
|
Auersperg, N.
(1964)
J. Natl. Cancer Inst.
32,
135-163
|
| 25.
|
Friedl, F.,
Kimura, I.,
Osato, T.,
and Ito, Y.
(1970)
Proc. Soc. Exp. Biol. Med.
135,
543-545[Medline]
[Order article via Infotrieve]
|
| 26.
|
Yee, C.,
Krishnan-Hewlett, I.,
Baker, C. C.,
Schlegel, R.,
and Howley, P. M.
(1985)
Am. J. Pathol.
119,
361-366[Abstract]
|
| 27.
|
Smith, M. D.,
Dawson, S. J.,
and Latchman, D. S.
(1997)
Mol. Cell. Biol.
17,
345-354[Abstract]
|
| 28.
|
Lakin, N. D.,
Morris, P. J.,
Theil, T.,
Sato, T. N.,
Moroy, T.,
Wilson, M. C.,
and Latchman, D. S.
(1995)
J. Biol. Chem.
270,
15858-15863[Abstract/Free Full Text]
|
| 29.
|
von Knebel Doeberitz, M.,
Oltersdorf, T.,
Schwarz, E.,
and Gissmann, L.
(1988)
Cancer Res.
48,
3780-3786[Abstract/Free Full Text]
|
| 30.
|
Gorman, C. M.
(1985)
in
DNA Cloning, a Practical Approach
(Glover, D. M., ed), Vol. 2
, pp. 143-190, IRL Press at Oxford University Press, Oxford
|
Copyright © 1999 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
E. Ensor, M. D. Smith, and D. S. Latchman
The BRN-3A Transcription Factor Protects Sensory but Not Sympathetic Neurons from Programmed Cell Death/Apoptosis
J. Biol. Chem.,
February 9, 2001;
276(7):
5204 - 5212.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 1999 by the American Society for Biochemistry and Molecular Biology.